Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
406.79
-3.86 (-0.94%)
Dec 27, 2024, 10:41 AM EST - Market open
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B in the quarter ending September 30, 2024, with 11.61% growth. This brings the company's revenue in the last twelve months to $10.63B, up 10.06% year-over-year. In the year 2023, Vertex Pharmaceuticals had annual revenue of $9.87B with 10.51% growth.
Revenue (ttm)
$10.63B
Revenue Growth
+10.06%
P/S Ratio
9.97
Revenue / Employee
$1,967,741
Employees
5,400
Market Cap
104.76B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | 4.16B | 1.12B | 36.59% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Cigna Group | 229.75B |
Elevance Health | 174.02B |
HCA Healthcare | 69.62B |
Sanofi | 54.03B |
Bristol-Myers Squibb Company | 47.44B |
Medtronic | 33.00B |
Gilead Sciences | 28.30B |
Stryker | 21.97B |
VRTX News
- 3 days ago - Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 - Business Wire
- 3 days ago - Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst - Benzinga
- 6 days ago - US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment - Reuters
- 6 days ago - Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
- 6 days ago - Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants - Business Wire
- 7 days ago - Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation - Accesswire
- 7 days ago - Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? - Benzinga
- 7 days ago - Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm - GlobeNewsWire